Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00675857 | A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes | PHASE2 | COMPLETED | 200 | — | — | Apr 1, 2008 | May 1, 2010 | Aug 24, 2010 | 21 | Canada |
| Arm | Type | Description |
|---|---|---|
| A | PLACEBO_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NC-503 (eprodisate disodium) | DRUG | capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks |
| placebo | OTHER | Dosage: 4 capsules BID for 26 weeks |
Inclusion Criteria: * Age and gender eligibility: 30 years and older * Diagnosis of Type 2 diabetes mellitus * Patients treated with a stable therapeutic dose of either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent for a minimum period of 3 months prior to t...